These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23463584)

  • 1. Gene delivery of albumin binding peptide-interferon-gamma fusion protein with improved pharmacokinetic properties and sustained biological activity.
    Miyakawa N; Nishikawa M; Takahashi Y; Ando M; Misaka M; Watanabe Y; Takakura Y
    J Pharm Sci; 2013 Sep; 102(9):3110-8. PubMed ID: 23463584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged circulation half-life of interferon γ activity by gene delivery of interferon γ-serum albumin fusion protein in mice.
    Miyakawa N; Nishikawa M; Takahashi Y; Ando M; Misaka M; Watanabe Y; Takakura Y
    J Pharm Sci; 2011 Jun; 100(6):2350-7. PubMed ID: 21246562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Delivery of Interferon Gamma Using a Recombinant Fusion Protein of a Fibrin Clot-Binding Peptide With Interferon Gamma for Cancer Gene Therapy.
    Ando M; Fujimoto M; Takahashi Y; Nishikawa M; Hamana A; Takakura Y
    J Pharm Sci; 2017 Mar; 106(3):892-897. PubMed ID: 27939375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Control of spatiotemporal distribution of interferon γ by genetically fusing functional peptides].
    Ando M; Takahashi Y; Nishikawa M; Takakura Y
    Yakugaku Zasshi; 2012; 132(12):1399-406. PubMed ID: 23208047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide-modified albumin carrier explored as a novel strategy for a cell-specific delivery of interferon gamma to treat liver fibrosis.
    Bansal R; Prakash J; de Ruijter M; Beljaars L; Poelstra K
    Mol Pharm; 2011 Oct; 8(5):1899-909. PubMed ID: 21800888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and characterization of albumin fusion protein canine IFNγ-CSA in baculovirus-insect cell expression system.
    Li B; Wu J; Zou S; Zhai J; Chen A; Bu W; Chen R; Luo M
    Protein Expr Purif; 2019 Oct; 162():32-37. PubMed ID: 31100416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved anti-cancer effect of interferon gene transfer by sustained expression using CpG-reduced plasmid DNA.
    Kawano H; Nishikawa M; Mitsui M; Takahashi Y; Kako K; Yamaoka K; Watanabe Y; Takakura Y
    Int J Cancer; 2007 Jul; 121(2):401-6. PubMed ID: 17372909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice.
    Melder RJ; Osborn BL; Riccobene T; Kanakaraj P; Wei P; Chen G; Stolow D; Halpern WG; Migone TS; Wang Q; Grzegorzewski KJ; Gallant G
    Cancer Immunol Immunother; 2005 Jun; 54(6):535-47. PubMed ID: 15592670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies.
    Mizokami MM; Hu P; Khawli LA; Li J; Epstein AL
    Hybrid Hybridomics; 2003 Aug; 22(4):197-207. PubMed ID: 14511565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL.
    Li R; Yang H; Jia D; Nie Q; Cai H; Fan Q; Wan L; Li L; Lu X
    J Control Release; 2016 Apr; 228():96-106. PubMed ID: 26951928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of human interferon gamma and tumor Necrosis factor alpha chimeric TNT-3 fusion proteins.
    Sharifi J; Khawli LA; Hu P; Li J; Epstein AL
    Hybrid Hybridomics; 2002 Dec; 21(6):421-32. PubMed ID: 12573106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intramuscular administration of expression plasmids encoding interferon-gamma receptor/IgG1 or IL-4/IgG1 chimeric proteins protects from autoimmunity.
    Chang Y; Prud'homme GJ
    J Gene Med; 1999; 1(6):415-23. PubMed ID: 10753067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein.
    Hopp J; Hornig N; Zettlitz KA; Schwarz A; Fuss N; Müller D; Kontermann RE
    Protein Eng Des Sel; 2010 Nov; 23(11):827-34. PubMed ID: 20817756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Albumin fusion improves the pharmacokinetics and in vivo antitumor efficacy of canine interferon gamma.
    Li B; Chen A; Zou S; Wu J; Wang H; Chen R; Luo M
    Int J Pharm; 2019 Mar; 558():404-412. PubMed ID: 30639219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Balancing the pharmacokinetics and pharmacodynamics of interferon-α2b and human serum albumin fusion protein by proteolytic or reductive cleavage increases its in vivo therapeutic efficacy.
    Zhao HL; Xue C; Du JL; Ren M; Xia S; Liu ZM
    Mol Pharm; 2012 Mar; 9(3):664-70. PubMed ID: 22224503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo cutaneous interferon-gamma gene delivery using novel dicationic (gemini) surfactant-plasmid complexes.
    Badea I; Verrall R; Baca-Estrada M; Tikoo S; Rosenberg A; Kumar P; Foldvari M
    J Gene Med; 2005 Sep; 7(9):1200-14. PubMed ID: 15895387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and bioactivity of recombinant human serum albumin and dTMP fusion proteins in CHO cells.
    Ru Y; Zhi D; Guo D; Wang Y; Li Y; Wang M; Wei S; Wang H; Wang N; Che J; Li H
    Appl Microbiol Biotechnol; 2016 Sep; 100(17):7565-75. PubMed ID: 27115755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of adverse events of interferon γ gene therapy by gene delivery of interferon γ-heparin-binding domain fusion protein in mice.
    Ando M; Takahashi Y; Yamashita T; Fujimoto M; Nishikawa M; Watanabe Y; Takakura Y
    Mol Ther Methods Clin Dev; 2014; 1():14023. PubMed ID: 26015966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PEGylation improves pharmacokinetic profile, liver uptake and efficacy of Interferon gamma in liver fibrosis.
    Bansal R; Post E; Proost JH; de Jager-Krikken A; Poelstra K; Prakash J
    J Control Release; 2011 Sep; 154(3):233-40. PubMed ID: 21664391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intact bioactivities and improved pharmacokinetic of the SL335-IFN-β-1a fusion protein that created by genetic fusion of SL335, a human anti-serum albumin fab, and human interferon-β.
    Ji SI; Park JH; You HG; Chi HJ; Bang YW; Cha SH
    Immunol Lett; 2019 Mar; 207():46-55. PubMed ID: 30684504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.